Serotonin in the gastrointestinal tract

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Purpose of review: To assess the role of serotonin and its control in the manifestations and treatment of lower functional gastrointestinal disorders. Recent findings: Recent literature has explored several novel concepts in the association of serotonin and symptoms, alterations in tissue levels of serotonin and its reuptake protein, aspects of the genetic determinants of serotonergic function (particularly 5-HTTLPR) and its relationship to gastrointestinal motor and sensory functions, and novel serotonergic agents used in therapy of lower functional gastrointestinal disorders. The most consistent findings are the increase in plasma 5-hydroxytryptamine (5-HT) in diarrheal diseases and reduction in constipation. The serotonin transporter in platelets has an impact on the circulating level of 5-HT. Meta-analysis shows that 5-HTTLPR genotype is not significantly associated with irritable bowel syndrome in Whites or Asians. New 5-HT3 antagonists and 5-HT4 agonists are efficacious and promise to provide relief for patients if they can pass regulatory hurdles. Summary: Although the most relevant implication for clinical practice remains the evidence that serotonergic agents are efficacious in the treatment of chronic constipation, chronic diarrhea and irritable bowel syndrome, the role of genetic control of 5-HT and its receptors is the subject of ongoing research, and is likely to enhance understanding of the mechanisms and treatment of these diseases.

Original languageEnglish (US)
Pages (from-to)53-59
Number of pages7
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
Volume16
Issue number1
DOIs
StatePublished - Feb 2009

Fingerprint

Gastrointestinal Tract
Serotonin
Serotonin Agents
Irritable Bowel Syndrome
Gastrointestinal Diseases
Constipation
Serotonin 5-HT4 Receptor Agonists
Serotonin 5-HT3 Receptor Antagonists
Serotonin Plasma Membrane Transport Proteins
Serotonin Receptors
Therapeutics
Meta-Analysis
Diarrhea
Genotype
Research
Proteins

Keywords

  • 5-HT antagonist
  • ATI-7505
  • Genotype
  • Irritable bowel syndrome
  • Prucalopride
  • Reuptake
  • Serotonin transporter
  • TD-5108

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Nutrition and Dietetics

Cite this

Serotonin in the gastrointestinal tract. / Camilleri, Michael.

In: Current Opinion in Endocrinology, Diabetes and Obesity, Vol. 16, No. 1, 02.2009, p. 53-59.

Research output: Contribution to journalArticle

@article{2b9d489fd86f4adba1bdb825d14c66c2,
title = "Serotonin in the gastrointestinal tract",
abstract = "Purpose of review: To assess the role of serotonin and its control in the manifestations and treatment of lower functional gastrointestinal disorders. Recent findings: Recent literature has explored several novel concepts in the association of serotonin and symptoms, alterations in tissue levels of serotonin and its reuptake protein, aspects of the genetic determinants of serotonergic function (particularly 5-HTTLPR) and its relationship to gastrointestinal motor and sensory functions, and novel serotonergic agents used in therapy of lower functional gastrointestinal disorders. The most consistent findings are the increase in plasma 5-hydroxytryptamine (5-HT) in diarrheal diseases and reduction in constipation. The serotonin transporter in platelets has an impact on the circulating level of 5-HT. Meta-analysis shows that 5-HTTLPR genotype is not significantly associated with irritable bowel syndrome in Whites or Asians. New 5-HT3 antagonists and 5-HT4 agonists are efficacious and promise to provide relief for patients if they can pass regulatory hurdles. Summary: Although the most relevant implication for clinical practice remains the evidence that serotonergic agents are efficacious in the treatment of chronic constipation, chronic diarrhea and irritable bowel syndrome, the role of genetic control of 5-HT and its receptors is the subject of ongoing research, and is likely to enhance understanding of the mechanisms and treatment of these diseases.",
keywords = "5-HT antagonist, ATI-7505, Genotype, Irritable bowel syndrome, Prucalopride, Reuptake, Serotonin transporter, TD-5108",
author = "Michael Camilleri",
year = "2009",
month = "2",
doi = "10.1097/MED.0b013e32831e9c8e",
language = "English (US)",
volume = "16",
pages = "53--59",
journal = "Current Opinion in Endocrinology, Diabetes and Obesity",
issn = "1752-296X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Serotonin in the gastrointestinal tract

AU - Camilleri, Michael

PY - 2009/2

Y1 - 2009/2

N2 - Purpose of review: To assess the role of serotonin and its control in the manifestations and treatment of lower functional gastrointestinal disorders. Recent findings: Recent literature has explored several novel concepts in the association of serotonin and symptoms, alterations in tissue levels of serotonin and its reuptake protein, aspects of the genetic determinants of serotonergic function (particularly 5-HTTLPR) and its relationship to gastrointestinal motor and sensory functions, and novel serotonergic agents used in therapy of lower functional gastrointestinal disorders. The most consistent findings are the increase in plasma 5-hydroxytryptamine (5-HT) in diarrheal diseases and reduction in constipation. The serotonin transporter in platelets has an impact on the circulating level of 5-HT. Meta-analysis shows that 5-HTTLPR genotype is not significantly associated with irritable bowel syndrome in Whites or Asians. New 5-HT3 antagonists and 5-HT4 agonists are efficacious and promise to provide relief for patients if they can pass regulatory hurdles. Summary: Although the most relevant implication for clinical practice remains the evidence that serotonergic agents are efficacious in the treatment of chronic constipation, chronic diarrhea and irritable bowel syndrome, the role of genetic control of 5-HT and its receptors is the subject of ongoing research, and is likely to enhance understanding of the mechanisms and treatment of these diseases.

AB - Purpose of review: To assess the role of serotonin and its control in the manifestations and treatment of lower functional gastrointestinal disorders. Recent findings: Recent literature has explored several novel concepts in the association of serotonin and symptoms, alterations in tissue levels of serotonin and its reuptake protein, aspects of the genetic determinants of serotonergic function (particularly 5-HTTLPR) and its relationship to gastrointestinal motor and sensory functions, and novel serotonergic agents used in therapy of lower functional gastrointestinal disorders. The most consistent findings are the increase in plasma 5-hydroxytryptamine (5-HT) in diarrheal diseases and reduction in constipation. The serotonin transporter in platelets has an impact on the circulating level of 5-HT. Meta-analysis shows that 5-HTTLPR genotype is not significantly associated with irritable bowel syndrome in Whites or Asians. New 5-HT3 antagonists and 5-HT4 agonists are efficacious and promise to provide relief for patients if they can pass regulatory hurdles. Summary: Although the most relevant implication for clinical practice remains the evidence that serotonergic agents are efficacious in the treatment of chronic constipation, chronic diarrhea and irritable bowel syndrome, the role of genetic control of 5-HT and its receptors is the subject of ongoing research, and is likely to enhance understanding of the mechanisms and treatment of these diseases.

KW - 5-HT antagonist

KW - ATI-7505

KW - Genotype

KW - Irritable bowel syndrome

KW - Prucalopride

KW - Reuptake

KW - Serotonin transporter

KW - TD-5108

UR - http://www.scopus.com/inward/record.url?scp=58849165361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849165361&partnerID=8YFLogxK

U2 - 10.1097/MED.0b013e32831e9c8e

DO - 10.1097/MED.0b013e32831e9c8e

M3 - Article

C2 - 19115522

AN - SCOPUS:58849165361

VL - 16

SP - 53

EP - 59

JO - Current Opinion in Endocrinology, Diabetes and Obesity

JF - Current Opinion in Endocrinology, Diabetes and Obesity

SN - 1752-296X

IS - 1

ER -